US Advanced Purchases For COVID Drugs A Model Post-Pandemic? Not Likely, Manufacturers Warn
Executive Summary
Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.